This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

CytRx Announces Issuance Of European Patent Covering INNO-206 Linker Technology

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company specializing in oncology, today announced that the European Patent Office (EPO) has issued a patent covering the Company’s tumor-targeting linker platform technology and pharmaceutical compositions. CytRx also unveiled aldoxorubucin as the new generic name for INNO-206, the conjugate comprised of the protein-binding linker technology and the commonly prescribed chemotherapeutic drug doxorubicin.

“We now have broad intellectual property exclusivity for our protein-binding linker technology in the U.S. and the European Union,” said CytRx President and CEO Steven A. Kriegsman. “This is particularly exciting coming on the heels of our recent presentation at the American Society of Clinical Oncology (ASCO) conference of favorable results from our aldoxorubicin Phase 1b/2 clinical trial in patients with advanced sarcomas whose tumors had progressed after receiving other chemotherapies. These results increase our confidence in the linker technology’s ability to deliver doxorubicin in substantially higher concentrations to the tumor, while avoiding many of the severe side effects associated with the systemic delivery of unconjugated doxorubicin.”

CytRx holds the exclusive worldwide rights to the single-molecule linker technology, which is licensed from the Tumor Biology Institute in Freiburg, Germany. The linker is directly conjugated to a chemotherapeutic agent and when injected into the bloodstream binds to circulating albumin within minutes. The albumin-bound conjugate concentrates at the tumor site where the chemotherapeutic agent then is released from the linker.

“The technology can be used with multiple chemotherapeutic agents, making it in effect its own potential drug pipeline with blockbuster possibilities,” added Mr. Kriegsman.

Results from a Phase 1b/2 clinical trial showed clinical benefit (defined as partial response and stable disease of more than four months) following treatment with aldoxorubicin in 10 of 13 (77%) evaluable patients with relapsed or refractory soft tissue sarcoma. The trial data were presented earlier this month at the ASCO conference. CytRx is currently conducting an international Phase 2b clinical trial comparing aldoxorubicin with native doxorubicin as a first-line therapy in patients with soft tissue sarcomas, and is entering patients with advanced pancreatic ductual adenocarcinomas in a Phase 2 trial to evaluate treatment with aldoxorubicin. The Company plans to meet with the FDA in the second half of 2012 to discuss a potential Phase 3 pivotal trial for aldoxorubicin as therapy for patients with soft tissue sarcomas who have relapsed after or were refractory to chemotherapy.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,056.71 -14.51 -0.08%
S&P 500 1,977.80 0.00 0.00%
NASDAQ 4,507.1070 +1.2550 0.03%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs